Eszter Lajkó

Dr. Eszter Lajkó

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LDLevente E. Dókus
Levente E. Dókus
ELEszter Lajkó
Eszter Lajkó
IRIvan Ranđelović
Ivan Ranđelović
DMDiána Mező
Diána Mező
GSGitta Schlosser
Gitta Schlosser
Gábor MezőGábor Mező
Gábor Mező
The Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and dangerous cancerous diseases, leading to a high rate of mortality. Therefore, the development of new, more efficient treatment approaches is necessary to cure this illness. Peptide-based drug targeting provides a new tool for this purpose. Previously, a hexapeptide Cys-Lys-Ala-Ala-Lys-Asn (CKAAKN) was applied efficiently as the homing device for drug-loaded nanostructures in PDAC cells. In this research, Cys was replaced by Ser in the sequence and this new SKAAKN targeting moiety was used in conjugates containing daunomycin (Dau). Five different structures were developed and tested. The results indicated that linear versions with one Dau were not effective on PANC-1 cells in vitro; however, branched conjugates with two Dau molecules showed significant antitumor activity. Differences in the antitumor effect of the conjugates could be explained with the different cellular uptake and lysosomal degradation. The most efficient conjugate was Dau=Aoa-GFLG-K(Dau=Aoa)SKAAKN-OH (conjugate 4) that also showed significant tumor growth inhibition on s.c. implanted PANC-1 tumor-bearing mice with negligible side effects. Our novel results suggest that peptide-based drug delivery systems could be a promising tool for the treatment of pancreatic cancers.

18 December 2015 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
ELEszter Lajkó
Eszter Lajkó
PBPéter Bányai
Péter Bányai
ZZZsófia Zámbó
Zsófia Zámbó
LKLászló Kursinszki
László Kursinszki
ÉSÉva Szőke
Éva Szőke
Köhidai LászlóKöhidai László
Köhidai László
Alizarin and purpurin are di- and trihydroxyanthraquinones derived from Rubia tinctorum L. Previous pharmacological studies have demonstrated that they exhibit certain degree of selective inhibitory effects towards cancer cells suggesting their application as a targeted drug for cancer. Our present work was aimed to investigate the suitability of hydroxyanthraquinones of Rubia tinctorum L. for targeted tumor therapy. The effects of alizarin, purpurin and an aqueous extract from transformed hairy root culture of Rubia tinctorum L. were examined on (1) cell proliferation, (2) apoptosis, (3) cell adhesion/morphology and (4) migration (chemotaxis, chemokinesis) of human melanoma cell lines (A2058, HT168-M1) and human fibroblast cells (MRC-5), as well as (5) the aqueous extract was analytically characterized. The aqueous extract was prepared from R. tinctorum hairy root culture and qualitatively analyzed by HPLC and ESI–MS methods. The cell growth inhibitory activity of anthraquinones was evaluated by MTT-assay and by flow cytometry. The effect of anthraquinones on cell adhesion was measured by an impedance based technique, the xCELLigence SP. For the chemotaxis assay NeuroProbe® chamber was used. Computer based holographic microscopy was applied to analyze chemokinetic responses as well as morphometry. Statistical significance was determined by the one-way ANOVA test. In the aqueous extract, munjistin (Mr = 284, tR = 18.4 min) as a principal component and three minor anthraquinones (pseudopurpurin, rubiadin and nordamnacanthal) were identified. The purpurin elicited a stronger but not apoptosis-mediated antitumor effect in melanoma cells (A2058: 10−6–10−5 M: 90.6–64.1 %) than in normal fibroblasts (10−6–10−5 M: 97.6–84.8 %). The aqueous extract in equimolar concentrations showed the most potent cytotoxicity after 72 h incubation (A2058: 10−6–10−5 M: 87.4–55.0 %). All tested substances elicited chemorepellent effect in melanoma cells, while in MRC-5 fibroblasts, only the alizarin exhibited such a repellent character. Indices of chemokinesis measured by holographic microscopy (migration, migration directness, motility and motility speed) were significantly enhanced by alizarin and purpurin as well, while morphometric changes were weak in the two melanoma cell lines. Our results highlight the effective and selective inhibitory activity of purpurin towards melanoma cells and its possible use as a targeted anticancer agent. The anthraquinones of the cytotoxic extract are suggested to apply in drug delivery systems as an anticancer drug.

11 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Tamás JerneiTamás Jernei
Tamás Jernei
CDCintia Duró
Cintia Duró
ADAntonio Dembo
Antonio Dembo
ELEszter Lajkó
Eszter Lajkó
ATAngéla Takács
Angéla Takács
Antal CsampaiAntal Csampai
Antal Csampai
By means of copper(I)-and ruthenium(II)-catalyzed click reactions of quinine- and quinidine-derived alkynes with azide-substituted chalcones a systematic series of novel cinchona-chalcone hybrid compounds, containing 1,4-disubstituted- and 1,5-disubstituted 1,2,3-triazole linkers, were synthesized and evaluated for their cytotoxic activity on four human malignant cell lines (PANC-1, COLO-205, A2058 and EBC-1). In most cases, the cyclization reactions were accompanied by the transition-metal-catalyzed epimerization of the C9-stereogenic centre in the cinchona fragment. The results of the in vitro assays disclosed that all the prepared hybrids exhibit marked cytotoxicity in concentrations of low micromolar range, while the C9-epimerized model comprising quinidine- and (E)-1-(4-(3-oxo-3-(3,4,5-trimethoxyphenyl)prop-1-en-1-yl)phenyl) fragments, connected by 1,5-disubstituted 1,2,3-triazole linker, and can be regarded as the most potent lead of which activity is probably associated with a limited conformational space allowing for the adoption of a relatively rigid well-defined conformation identified by DFT modelling. The mechanism of action of this hybrid along with that of a model with markedly decreased activity were approached by comparative cell-cycle analyses in PANC-1 cells. These studies disclosed that the hybrid of enhanced antiproliferative activity exerts significantly more extensive inhibitory effects in subG1, S and G2/M phases than does the less cytotoxic counterpart.

5 March 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MKMárton Kalabay
Márton Kalabay
ZSZsófia Szász
Zsófia Szász
OLOrsolya Lang
Orsolya Lang
ELEszter Lajkó
Eszter Lajkó
ÉPÉva Pállinger
Éva Pállinger
Köhidai LászlóKöhidai László
Köhidai László
Tamoxifen is a long-known anti-tumor drug, which is the gold standard therapy in estrogen receptor (ER) positive breast cancer patients. According to previous studies, the conjugation of the original tamoxifen molecule with different functional groups can significantly improve its antitumor effect. The purpose of this research was to uncover the molecular mechanisms behind the cytotoxicity of different ferrocene-linked tamoxifen derivates. Tamoxifen and its ferrocene-linked derivatives, T5 and T15 were tested in PANC1, MCF7, and MDA-MB-231 cells, where the incorporation of the ferrocene group improved the cytotoxicity on all cell lines. PANC1, MCF7, and MDA-MB-231 express ERα and GPER1 (G-protein coupled ER 1). However, ERβ is only expressed by MCF7 and MDA-MB-231 cells. Tamoxifen is a known agonist of GPER1, a receptor that can promote tumor progression. Analysis of the protein expression profile showed that while being cytotoxic, tamoxifen elevated the levels of different tumor growth-promoting factors (e.g., Bcl-XL, Survivin, EGFR, Cathepsins, chemokines). On the other hand, the ferrocene-linked derivates were able to lower these proteins. Further analysis showed that the ferrocene-linked derivatives significantly elevated the cellular oxidative stress compared to tamoxifen treatment. In conclusion, we were able to find two molecules possessing better cytotoxicity compared to their unmodified parent molecule while also being able to counter the negative effects of the presence of the GPER1 through the ER-independent mechanism of oxidative stress induction.

19 May 2020 in Soft Matter
Verified
Journal Article
Open access
PDF file
LPLilla Pethő
Lilla Pethő
György KaszaGyörgy Kasza
György Kasza
ELEszter Lajkó
Eszter Lajkó
OLOrsolya Láng
Orsolya Láng
LKLászló Kőhidai
László Kőhidai
Gábor MezőGábor Mező
Gábor Mező
EGFR targeting drug–polymer–peptide conjugates have enhanced solubility wherein in vitro biological activity highly depends on the structure of conjugates due to their amphiphilic character and self-aggregation properties.

13 January 2018 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
ELEszter Lajkó
Eszter Lajkó
BTBernadett Tuka
Bernadett Tuka
FFFerenc Fulop
Ferenc Fulop
IKIstván A. Krizbai
István A. Krizbai
JTJozsef Toldi
Jozsef Toldi
Köhidai LászlóKöhidai László
Köhidai László